Literature DB >> 15839717

Use of antidepressants in older patients with co-morbid medical conditions: guidance from studies of depression in somatic illness.

Gary J Kennedy1, Paula Marcus.   

Abstract

Advanced age and medical complexity are characteristics not often associated with participation in randomised, placebo-controlled trials of antidepressants. Thus, evidence for the efficacy of antidepressant treatment among typical seniors with somatic illness and advanced age is scant. Furthermore, there appears to be no clear empirically based delineation between depressive symptoms and depressive disorders among very old, physically ill adults. The increasing numbers of antidepressants and adjunctive medications add to the practitioner's perplexity when confronted with a very old, very depressed patient. Nonetheless, a growing body of evidence from antidepressant studies in the context of age-related somatic illnesses allows reasonable inferences to guide diagnosis and treatment. Once the practitioner and patient agree upon an antidepressant trial, the benefits of prescribed medication should be assessed within the first days rather than first weeks of treatment. The patient and practitioner should expect to escalate the antidepressant to the established therapeutic range rather than seek the lowest dose that is effective. Patients who experience no benefit whatsoever within the first weeks of treatment despite being within the therapeutic range should be offered an alternative promptly. With the results of studies of depression in co-morbid disorders and analyses of treatment response trajectory, the practitioner can be assured that advanced age, physical illness and depression need not go hand in hand.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15839717     DOI: 10.2165/00002512-200522040-00001

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  110 in total

1.  Use of antidepressants among elderly subjects: trends and contributing factors.

Authors:  M M Mamdani; S V Parikh; P C Austin; R E Upshur
Journal:  Am J Psychiatry       Date:  2000-03       Impact factor: 18.112

2.  Risk factors for falls during treatment of late-life depression.

Authors:  Jin H Joo; Eric J Lenze; Benoit H Mulsant; Amy E Begley; Elizabeth M Weber; Jacqueline A Stack; Sati Mazumdar; Charles F Reynolds; Bruce G Pollock
Journal:  J Clin Psychiatry       Date:  2002-10       Impact factor: 4.384

3.  Drug treatment of depression in frail elderly nursing home residents.

Authors:  J E Streim; D W Oslin; I R Katz; B D Smith; S DiFilippo; T B Cooper; T Ten Have
Journal:  Am J Geriatr Psychiatry       Date:  2000       Impact factor: 4.105

4.  Seven chronic conditions: their impact on US adults' activity levels and use of medical services.

Authors:  L M Verbrugge; D L Patrick
Journal:  Am J Public Health       Date:  1995-02       Impact factor: 9.308

5.  Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine.

Authors:  Michael E Thase; Pierre V Tran; Curtis Wiltse; Beth A Pangallo; Craig Mallinckrodt; Michael J Detke
Journal:  J Clin Psychopharmacol       Date:  2005-04       Impact factor: 3.153

Review 6.  Clinically significant non-major depression: old concepts, new insights.

Authors:  Helen Lavretsky; Anand Kumar
Journal:  Am J Geriatr Psychiatry       Date:  2002 May-Jun       Impact factor: 4.105

7.  Consequences of major and minor depression in later life: a study of disability, well-being and service utilization.

Authors:  A T Beekman; D J Deeg; A W Braam; J H Smit; W Van Tilburg
Journal:  Psychol Med       Date:  1997-11       Impact factor: 7.723

Review 8.  Practical considerations for the treatment of depression in elderly and very elderly long-term care patients.

Authors:  C Salzman
Journal:  J Clin Psychiatry       Date:  1999       Impact factor: 4.384

Review 9.  Safety and tolerability of lamotrigine for bipolar disorder.

Authors:  Charles L Bowden; Gregory M Asnis; Lawrence D Ginsberg; Beth Bentley; Robert Leadbetter; Robin White
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

10.  Metabolic and physiologic consequences of nortriptyline treatment in the elderly.

Authors:  B G Pollock; J M Perel; C F Paradis; A L Fasiczka; C F Reynolds
Journal:  Psychopharmacol Bull       Date:  1994
View more
  5 in total

1.  Under-treatment of depression in older persons.

Authors:  Lisa C Barry; Janet J Abou; Arthur A Simen; Thomas M Gill
Journal:  J Affect Disord       Date:  2011-10-26       Impact factor: 4.839

2.  Clinical effectiveness of integrating depression care management into medicare home health: the Depression CAREPATH Randomized trial.

Authors:  Martha L Bruce; Patrick J Raue; Catherine F Reilly; Rebecca L Greenberg; Barnett S Meyers; Samprit Banerjee; Yolonda R Pickett; Thomas F Sheeran; Angela Ghesquiere; Diane M Zukowski; Vianca H Rosas; Jeanne McLaughlin; Lori Pledger; Joan Doyle; Pamela Joachim; Andrew C Leon
Journal:  JAMA Intern Med       Date:  2015-01       Impact factor: 21.873

3.  The use of antidepressants in Belgian nursing homes: focus on indications and dosages in the PHEBE study.

Authors:  Jolyce Bourgeois; Monique M Elseviers; Luc Van Bortel; Mirko Petrovic; Robert H Vander Stichele
Journal:  Drugs Aging       Date:  2012-09       Impact factor: 3.923

4.  Similar effects of low to moderate-intensity exercise program vs moderate-intensity continuous exercise program on depressive disorder in heart failure patients: A 12-week randomized controlled trial.

Authors:  Walid Kamal Abdelbasset; Bader A Alqahtani; Saud M Alrawaili; Ahmed S Ahmed; Tamer E Elnegamy; Ahmed A Ibrahim; Gaber S Soliman
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.889

5.  Examining the impacts of 12 weeks of low to moderate-intensity aerobic exercise on depression status in patients with systolic congestive heart failure - A randomized controlled study.

Authors:  Walid Kamal Abdelbasset; Bader A Alqahtani; Ahmed A Elshehawy; Sayed A Tantawy; Tamer E Elnegamy; Dalia M Kamel
Journal:  Clinics (Sao Paulo)       Date:  2019-09-26       Impact factor: 2.365

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.